Immuno-oncology efficacy is well mapped
“We know exactly where I-O [immuno-oncology] works, where a checkpoint inhibitor works, where it doesn’t, where it almost worked and didn’t make it,”
STAT Summit stage
On the same topic: Biotech & medicine
More →“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”
“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”
“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”